Throat cancer includes cancers of the larynx, pharynx, and surrounding areas, and outcomes vary by stage. In the US, hoarseness lasting over 2 weeks is reported in 60% of laryngeal cancer cases, but other symptoms can appear depending on the site. This page breaks down risk factors like smoking and heavy alcohol, common presentations, and what survival statistics can tell you.
Key Takeaways
- In the United States, approximately 12,230 new cases of laryngeal cancer are diagnosed annually as of 2023 estimates
- Globally, throat cancer accounts for about 1.3% of all new cancer cases, with 184,615 new cases reported in 2020
- The lifetime risk of developing laryngeal cancer is 0.5% for men and 0.2% for women in the US
- Overall 5-year relative survival for hypopharyngeal cancer is 28.4%
- Laryngeal cancer causes 3,770 deaths annually in the US (2023 est.)
- Global throat cancer mortality: 99,840 deaths in 2020
- Smoking increases throat cancer risk by 5 to 25 times compared to non-smokers
- Heavy alcohol consumption multiplies throat cancer risk by 5-fold when combined with smoking
- HPV-16 infection raises oropharyngeal cancer risk by 32-fold in men
- Hoarseness persisting over 2 weeks is the most common initial symptom in 60% of laryngeal cancer cases
- Dysphagia occurs in 50-70% of advanced hypopharyngeal cancers at diagnosis
- Neck mass from lymph nodes is present in 40% of oropharyngeal cancers initially
- 5-year survival for localized laryngeal cancer is 77.5% with early diagnosis
- Concurrent chemoradiation achieves 85-90% larynx preservation in stage III
- Surgery alone for T1 glottic cancer yields 95% local control rate
Related reading
01 · Category
Incidence And Prevalence30 stats
01
In the United States, approximately 12,230 new cases of laryngeal cancer are diagnosed annually as of 2023 estimates
02
Globally, throat cancer accounts for about 1.3% of all new cancer cases, with 184,615 new cases reported in 2020
03
The lifetime risk of developing laryngeal cancer is 0.5% for men and 0.2% for women in the US
04
In Europe, the age-standardized incidence rate for pharyngeal cancer is 2.5 per 100,000 in men and 0.7 in women
05
Among American Indians/Alaska Natives, the incidence rate of laryngeal cancer is 6.9 per 100,000, the highest among US racial/ethnic groups
06
In 2022, India reported over 72,000 new cases of oral and throat cancers combined
07
The incidence of oropharyngeal cancer has increased by 2.5% annually from 1999-2015 in the US due to HPV
08
In the UK, there are around 2,100 new cases of laryngeal cancer each year
09
SEER data shows 66,196 cases of laryngeal cancer from 1975-2019 in the US
10
Hypopharyngeal cancer incidence is 1.6 per 100,000 in men globally
11
Prevalence of throat cancer survivors in the US is about 5-year prevalence of 47,800 as of 2021
12
In China, throat cancer incidence rose 3.8% annually from 2003-2015
13
Australian men have an incidence rate of 3.2 per 100,000 for laryngeal cancer
14
HPV-related oropharyngeal cancer comprises 70% of cases in the US white population
15
In Brazil, 12,000 new throat cancer cases yearly, mostly in men over 50
16
Age-adjusted incidence of hypopharyngeal cancer is 0.4 per 100,000 women in the US
17
In Japan, oropharyngeal cancer incidence increased from 1.2 to 2.1 per 100,000 between 1993-2012
18
US Black men have laryngeal cancer incidence of 7.1 per 100,000
19
Global prevalence of laryngeal cancer is estimated at 200,000 living with the disease
20
In France, 3,500 new laryngeal cancer cases annually
21
SEER 21 registries report 3.2 new laryngeal cancer cases per 100,000 annually
22
Oropharyngeal squamous cell carcinoma incidence is 7.2 per 100,000 in US men
23
In South Korea, hypopharyngeal cancer incidence doubled from 1.5 to 3.2 per 100,000 in 10 years
24
Lifetime prevalence risk for throat cancer in US men is 0.77%
25
In Italy, 4,200 laryngeal cancer cases in 2020
26
HPV-positive oropharyngeal cancer rates rose 4.1-fold in last 30 years in US
27
In Canada, 1,400 new laryngeal cancer cases yearly
28
Age-specific incidence peaks at 70-74 years for laryngeal cancer globally
29
In the US, 66% of laryngeal cancers diagnosed at regional or distant stage
30
Global new cases of nasopharyngeal cancer: 133,000 in 2020, often grouped with throat
Interpretation
Incidence And Prevalence Interpretation
Overall, throat and related cancers remain a noticeable but relatively small share of cancer diagnoses worldwide with 184,615 new cases in 2020, while incidence is far from uniform as the United States reports 12,230 annual laryngeal cancers and rates rise sharply in specific groups, such as 6.9 per 100,000 among American Indians and Alaska Natives.
02 · Category
Mortality And Prognosis28 stats
01
Overall 5-year relative survival for hypopharyngeal cancer is 28.4%
02
Laryngeal cancer causes 3,770 deaths annually in the US (2023 est.)
03
Global throat cancer mortality: 99,840 deaths in 2020
04
5-year survival drops to 30.5% for regional stage laryngeal cancer
05
Distant stage hypopharyngeal cancer 5-year survival: 22.4%
06
Male mortality rate for laryngeal cancer: 2.4 per 100,000 in US
07
Recurrence within 2 years occurs in 50% of advanced throat cancers
08
Smoking cessation post-diagnosis improves 5-year survival by 20%
09
Extracapsular nodal spread halves 5-year survival to 40%
10
Median survival for metastatic disease: 10-12 months untreated
11
Positive margins post-surgery: 2.5-fold increased mortality risk
12
Perineural invasion present in 30% cases, worsens prognosis by 15%
13
T4 stage laryngeal cancer 5-year survival: 27.1%
14
Second primary tumors occur in 20% within 10 years, reducing OS
15
Comorbidity index predicts 30% higher mortality in treated patients
16
Distant metastasis to lungs in 60% of recurrent cases
17
10-year cause-specific survival stage II oropharynx: 65%
18
Unresectable disease median survival 6-9 months with palliative care
19
Cartilage invasion in larynx cancer reduces survival by 25%
20
Elderly (>75) have 2-fold higher perioperative mortality
21
Low hemoglobin <12 g/dL during RT worsens locoregional control 15%
22
N3 nodal disease 5-year survival <30%
23
Aspiration pneumonia post-treatment causes 10-15% of deaths
24
Global age-standardized mortality rate for larynx cancer: 0.9 per 100,000
25
Black patients have 1.5 times higher mortality than whites adjusted
26
Vascular embolism in pathology increases recurrence risk 3-fold
27
Late mortality from second smoking-related cancers: 30% at 10 years
28
Overall US laryngeal cancer mortality declined 1.6% annually 2012-2016
Interpretation
Mortality And Prognosis Interpretation
From a mortality and prognosis perspective, throat cancers show consistently poor long term outcomes, with hypopharyngeal cancer’s 5 year survival at 28.4% overall that falls to 22.4% for distant stage disease.
03 · Category
Risk Factors27 stats
01
Smoking increases throat cancer risk by 5 to 25 times compared to non-smokers
02
Heavy alcohol consumption multiplies throat cancer risk by 5-fold when combined with smoking
03
HPV-16 infection raises oropharyngeal cancer risk by 32-fold in men
04
Betel quid chewing increases hypopharyngeal cancer risk by 8.2 times (95% CI 6.3-10.6)
05
Occupational exposure to asbestos elevates laryngeal cancer risk by 1.5-2.0 times
06
GERD is associated with 2.8-fold increased risk of laryngeal cancer (OR=2.8, 95% CI 1.4-5.6)
07
Poor oral hygiene triples throat cancer risk due to chronic inflammation
08
Marijuana smoking linked to 2.6 times higher oropharyngeal cancer risk
09
Family history increases laryngeal cancer risk by 3.3-fold
10
Radiation exposure to neck raises hypopharyngeal cancer risk 4-10 years later by 2-fold
11
Obesity (BMI>30) associated with 1.8 times higher throat cancer risk
12
Smokeless tobacco use increases oral/pharyngeal cancer risk by 4-6 times
13
Chronic tonsillitis linked to 2.1-fold oropharyngeal cancer risk
14
HIV infection elevates throat cancer risk by 2.4 times adjusted for smoking
15
Areca nut chewing alone raises risk by 2.8 times (RR=2.8, 95% CI 1.4-5.4)
16
Male gender has 4-5 times higher throat cancer incidence than females
17
Age over 55 years accounts for 80% of laryngeal cancer diagnoses
18
Plummer-Vinson syndrome increases hypopharyngeal cancer risk 25-fold
19
EBV infection strongly linked to nasopharyngeal cancer risk (OR>10)
20
Passive smoking exposure increases laryngeal cancer risk by 1.4 times
21
Inverse association: fruit/vegetable intake reduces risk by 40-50%
22
Wood dust exposure in woodworking raises laryngeal cancer risk 1.4-2.5 fold
23
40+ pack-years smoking: 15-fold risk increase for supraglottic cancer
24
Alcohol >30g/day with smoking: synergistic 15-30 fold risk
25
Cannabis use >1 joint/day: OR=2.59 for head/neck cancer
26
Low socioeconomic status triples throat cancer risk due to lifestyle
27
Prior head/neck radiation: 5-10 fold increased risk
Interpretation
Risk Factors Interpretation
From the risk factors, the biggest standout trend is that high-impact exposures like HPV-16 can raise oropharyngeal cancer risk by as much as 32-fold while smoking also dramatically increases risk by 5 to 25 times, underscoring how strongly certain behaviors and infections drive throat cancer risk.
More related reading
04 · Category
Symptoms And Diagnosis30 stats
01
Hoarseness persisting over 2 weeks is the most common initial symptom in 60% of laryngeal cancer cases
02
Dysphagia occurs in 50-70% of advanced hypopharyngeal cancers at diagnosis
03
Neck mass from lymph nodes is present in 40% of oropharyngeal cancers initially
04
Ear pain (otalgia) due to referred pain in 30-50% of supraglottic laryngeal cancers
05
Weight loss >10% body weight in 40% of patients with stage III/IV throat cancer
06
Stridor or airway obstruction in 10-15% of advanced glottic cancers
07
Cough with hemoptysis in 20% of hypopharyngeal cancer patients
08
Voice change quality described as rough in 70% of early glottic cancers
09
Sore throat or globus sensation in 35% of oropharyngeal cases
10
Halitosis (bad breath) from tumor necrosis in 25% advanced cases
11
Asymmetry of throat or tonsil enlargement noted in 45% HPV+ oropharyngeal
12
Nasal obstruction or epistaxis in 20% nasopharyngeal throat cancers
13
Diagnosis confirmed by biopsy in 95% of suspected throat cancer cases
14
Flexible laryngoscopy detects 90% of laryngeal lesions
15
CT scan with contrast shows 85% accuracy for staging neck nodes
16
PET-CT has 92% sensitivity for detecting distant metastases in throat cancer
17
HPV testing via p16 immunohistochemistry positive in 70% oropharyngeal cancers
18
Fine-needle aspiration biopsy sensitivity 89% for cervical lymph nodes
19
Videostroboscopy identifies vocal cord mobility in 98% glottic cases
20
MRI superior for base of tongue tumors, delineating 95% tumor extent
21
Panendoscopy under anesthesia detects synchronous primaries in 10-15%
22
Barium swallow shows piriform sinus filling defects in 80% hypopharyngeal
23
Serum EBV DNA PCR sensitivity 96% for nasopharyngeal carcinoma diagnosis
24
70% of throat cancers diagnosed at stage III or IV due to late symptoms
25
Hoarseness duration average 4-6 months before diagnosis in glottic cancer
26
Neck CT detects extracapsular spread in 75% node-positive cases
27
Narrow band imaging improves detection of superficial lesions by 20%
28
Average age at diagnosis for laryngeal cancer is 66 years
29
Dysphonia severity index correlates with tumor stage in 85% cases
30
Ultrasound-guided FNA reduces non-diagnostic rates to 5%
Interpretation
Symptoms And Diagnosis Interpretation
In the Symptoms And Diagnosis picture, hoarseness lasting more than 2 weeks is the leading clue in 60% of laryngeal cancers, while other red flags like dysphagia in 50 to 70% of advanced hypopharyngeal cases and neck masses in 40% of oropharyngeal cancers help clinicians identify more advanced disease sooner.
05 · Category
Treatment And Survival Rates26 stats
01
5-year survival for localized laryngeal cancer is 77.5% with early diagnosis
02
Concurrent chemoradiation achieves 85-90% larynx preservation in stage III
03
Surgery alone for T1 glottic cancer yields 95% local control rate
04
HPV-positive oropharyngeal cancer 5-year OS 82% vs 55% HPV-negative
05
Total laryngectomy with postoperative RT: 65% 5-year survival stage IV
06
De-intensification trials show 93% 2-year survival with reduced RT dose
07
Cetuximab + RT improves median survival to 49 months vs RT alone 29 months
08
Transoral robotic surgery (TORS) for T1-2 oropharynx: 97% 3-year LRC
09
Induction chemotherapy response rate 80% predicts organ preservation
10
Intensity-modulated RT (IMRT) reduces xerostomia to 20% severe grade
11
Neck dissection + RT: 90% regional control for N2 disease
12
Pembrolizumab for PD-L1+ recurrent disease: 14.9-month median OS
13
Laser microsurgery for early glottic: 96% 5-year DFS
14
Adjuvant chemoRT post-surgery improves DFS by 10% in high-risk
15
10-year survival for stage I larynx cancer: 80-90%
16
Nivolumab in platinum-refractory: 7.5-month OS vs 5.1 historical
17
Voice rehabilitation post-laryngectomy: 70% achieve intelligible tracheoesophageal speech
18
Proton therapy reduces dysphagia by 50% vs IMRT in oropharyngeal
19
Salvage surgery success 40-60% for local recurrence post-RT
20
3-year PFS 78% with TORS + low-dose RT in HPV+ T1-2
21
Weekly cisplatin concurrent RT: 88% 5-year OS stage III larynx
22
Elective neck irradiation controls occult mets in 85% N0 cases
23
Immunotherapy response rate 20% in advanced head/neck squamous cell
24
Radiotherapy alone for T1A glottic: 95% local control at 5 years
25
Postoperative RT dose 60-66 Gy yields 70% control high-risk margins
26
5-year OS for distant metastatic throat cancer: 30-40%
Interpretation
Treatment And Survival Rates Interpretation
Across treatment approaches, survival and organ outcomes improve substantially with better-selected therapy and early intervention, such as 5-year survival reaching 77.5% for localized laryngeal cancer and 85 to 90% larynx preservation in stage III with concurrent chemoradiation, while HPV-positive oropharyngeal cancer shows markedly higher 5-year overall survival of 82% versus 55% when compared to HPV-negative disease.
report visual · Comparison
Throat Cancer Statistics statistics snapshot
Selected headline statistics from verified sources for a stable visual baseline.
HPV-related oropharyngeal cancer comprises 70% of cases in the US white population70%
In China, throat cancer incidence rose 3.8% annually from 2003-20153.8%
The incidence of oropharyngeal cancer has increased by 2.5% annually from 1999-2015 in the US due to HPV2.5%
Globally, throat cancer accounts for about 1.3% of all new cancer cases, with 184,615 new cases reported in 20201.3%
Lifetime prevalence risk for throat cancer in US men is 0.77%0.77%
The lifetime risk of developing laryngeal cancer is 0.5% for men and 0.2% for women in the US0.5%
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lukas Bauer. (2026, February 13). Throat Cancer Statistics. Gitnux. https://gitnux.org/throat-cancer-statistics
MLA
Lukas Bauer. "Throat Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/throat-cancer-statistics.
Chicago
Lukas Bauer. 2026. "Throat Cancer Statistics." Gitnux. https://gitnux.org/throat-cancer-statistics.
Sources & references
27 datasets cited across this report · attribution is report-level